Cancer Registry Software Market by Type (Standalone, Integration), Delivery (On-premise, Cloud), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care, Medical Research), End User, Region - Global Forecast to 2024

がん患者登録ソフトウェアの世界市場予測(~2024年)

◆タイトル:Cancer Registry Software Market by Type (Standalone, Integration), Delivery (On-premise, Cloud), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care, Medical Research), End User, Region - Global Forecast to 2024
◆商品コード:HIT-6993
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年3月28日
◆ページ数:125
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:ヘルスケアIT
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD11,000 ⇒換算¥1,177,000見積依頼/購入/質問フォーム
Multi User (Five User)USD13,000 ⇒換算¥1,391,000見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD15,000 ⇒換算¥1,605,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

がん患者登録ソフトウェアの世界市場は、2019年の5,500万米ドルから2024年には9,100万米ドルに達し、この期間中10.4%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、がんの罹患率の増加、政府による積極的な取り組み、EHRの採用の増加、市販直後調査を目的としたがん患者登録データの利用増加、医療の質の向上、医療費削減に対する意識の高まりなどが考えられます。一方で、プライバシーとデータセキュリティ関連の懸念により、市場の成長は抑制される可能性があります。当調査レポートでは、がん患者登録ソフトウェアの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、タイプ(スタンドアロン型、統合型)分析、導入モード(オンプレミス、クラウド)分析、データベース(民間、公共)分析、機能性(がん報告、患者ケア、医学研究)分析、がん患者登録ソフトウェアの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“Cancer patient registry software market projected to grow at a CAGR of 10.4%”
The cancer patient registry software market is projected to reach USD 91 million by 2024 from USD 55 million in 2019, at a CAGR of 10.4%. Factors such as the growing prevalence of cancer, favorable government initiatives, rising adoption of EHRs, growing use of cancer patient registry data for post-marketing surveillance, and rising pressure to improve the quality of care and reduce healthcare costs are driving the growth of this market. However, privacy and data security-related concerns may restrain the growth of this market to a certain extent.

“The on-premise model segment accounted for the largest share of the cancer patient registry software market, by deployment model, in 2018”

Based on deployment model, the cancer patient registry software market is segmented into on-premise and cloud-based models. The on-premise model segment dominated this market in 2018 primarily due to the higher adoption of on-premise solutions among end users as a result of advantages such as high security, low risk of external attacks and data breaches, and control over software upgrades. Also, this model enables flexibility of the connection bandwidth—a very important feature in cases where a client is dealing with heavy data file transfers.

“Commercial databases accounted for the largest share of the cancer patient registry software market, by database type, in 2018”

Based on the type of database, the cancer patient registry software market is segmented into commercial and public databases. The commercial databases segment dominated this market in 2018 owing to the ease of expansion of these databases, which allows a large user base to access, add, or modify information simultaneously. Also, owing to the advantages offered by commercial databases, a large number of pharmaceutical and medical device companies are opting for these databases.

“The medical research & clinical studies segment to witness the highest growth in the cancer patient registry software market, by functionality, during the forecast period”

Based on functionality, the cancer patient registry software market is segmented into cancer reporting to meet state and federal regulations, patient care management, product outcome evaluation, and medical research & clinical studies. The ability of cancer registries to provide data complementary to that obtained from trials for supporting medical research and clinical studies is one of the major factors driving the demand for cancer patient registry software for medical research and clinical studies.

“North American market to witness high growth during the forecast period”

In 2018, North America was the largest regional market for cancer patient registry software. This market is also estimated to grow at a higher CAGR during the forecast period. The high growth of this regional market can be attributed to the high burden of cancer, government funding initiatives to encourage the development of cancer registries, high investments in healthcare IT, presence of major cancer registry software-developing players, and the high adoption rate of these solutions in the region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 28%; Tier 2 – 19%; and Tier 3 – 53%
• By Designation: C-level – 51%; D-level – 28%; and Others – 21%
• By Region: North America – 70%; Europe – 30%
List of companies profiled in the report
• Elekta (Sweden)
• Electronic Registry Systems, Inc. (US)
• Onco, Inc. (US)
• C/NET Solutions (US)
• Rocky Mountain Cancer Data Systems (US)
• McKesson Corporation (US)
Research Coverage
This report aims at estimating the size and future growth potential of the market across different segments, such as type, deployment model, database, functionality, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report
This report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cancer patient registry software market and its subsegments. Also, this report will help stakeholders to better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 15
1.3.1 MARKETS COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 16
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 RESEARCH DATA 18
2.1.1 SECONDARY SOURCES 19
2.1.1.1 Key data from secondary sources 19
2.1.2 PRIMARY SOURCES 20
2.1.2.1 Key data from primary sources 21
2.1.2.2 Key industry insights 22
2.2 MARKET SIZE ESTIMATION 23
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 25
2.4 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHT 31
4.1 CANCER PATIENT REGISTRY SOFTWARE: MARKET OVERVIEW 31
4.2 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE 32
4.3 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL 32
4.4 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE 33
4.5 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY 33
4.6 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER 34

5 MARKET OVERVIEW 35
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 MARKET DRIVERS 36
5.2.1.1 Growing prevalence of cancer and favorable government initiatives 36
5.2.1.2 Rising pressure to improve the quality of care and reduce healthcare costs 36
5.2.1.3 Rising adoption of EHRs 37
5.2.1.4 Growing use of cancer patient registry data for post-marketing surveillance 37
5.2.2 MARKET RESTRAINTS 37
5.2.2.1 Privacy and data security-related concerns 37
5.2.3 MARKET OPPORTUNITIES 38
5.2.3.1 Rising number of accountable care organizations 38
5.2.3.2 Growth of cloud-based cancer patient registry solutions 38
5.2.4 MARKET CHALLENGES 38
5.2.4.1 Lack of interoperability and integration 38
5.2.4.2 Reluctance to adopt advanced solutions 39
5.2.4.3 Lack of awareness 39
6 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE 40
6.1 INTRODUCTION 41
6.2 STANDALONE SOFTWARE 42
6.2.1 STANDALONE SOFTWARE ACCOUNTS FOR THE LARGEST SHARE OF THE MARKET 42
6.3 INTEGRATED SOFTWARE 44
6.3.1 ADVANTAGES SUCH AS FLEXIBILITY AND SAFETY ARE DRIVING THE ADOPTION OF INTEGRATED SOFTWARE 44
7 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL 46
7.1 INTRODUCTION 47
7.2 ON-PREMISE MODELS 48
7.2.1 ON-PREMISE MODELS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2018 48
7.3 CLOUD-BASED MODELS 50
7.3.1 COST-EFFECTIVENESS AND FLEXIBILITY HAVE ENSURED THE GROWTH OF CLOUD-BASED MODELS 50

8 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE 52
8.1 INTRODUCTION 53
8.2 COMMERCIAL DATABASES 54
8.2.1 COMMERCIAL DATABASES SEGMENT HOLD THE LARGEST SHARE IN THE CANCER PATIENT REGISTRY SOFTWARE MARKET 54
8.3 PUBLIC DATABASES 56
8.3.1 PUBLIC DATABASES ARE USED FOR DATA COLLECTION FOR A SPECIFIC RESEARCH AGENDA 56
9 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY 58
9.1 INTRODUCTION 59
9.2 CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS 60
9.2.1 STRINGENT AND RAPIDLY CHANGING STATE AND FEDERAL REGULATIONS FOR CANCER REPORTING TO DRIVE THE GROWTH OF THIS SEGMENT 60
9.3 PATIENT CARE MANAGEMENT 62
9.3.1 MARKET PLAYERS ARE EXPECTED TO FOCUS ON DEVELOPING SOLUTIONS DESIGNED WITH AUTOMATED PATIENT OUTREACH FACILITY FOR OPTIMUM PATIENT CARE MANAGEMENT 62
9.4 MEDICAL RESEARCH & CLINICAL STUDIES 64
9.4.1 SEVERAL RESEARCH ORGANIZATIONS ARE EXPECTED TO SUPPORT AND ENCOURAGE THE CREATION OF REGISTRIES FOR CLINICAL RESEARCH 64
9.5 PRODUCT OUTCOME EVALUATION 66
9.5.1 PRODUCT OUTCOME EVALUATION FUNCTIONALITY HAS MAJOR APPLICATIONS IN POST-MARKETING SURVEILLANCE IN THE PHARMACEUTICAL INDUSTRY 66
10 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER 68
10.1 INTRODUCTION 69
10.2 GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS 70
10.2.1 GROWING GOVERNMENT INITIATIVES TO DRIVE THE DEMAND FOR CANCER PATIENT REGISTRY SOFTWARE IN THIS END-USER SEGMENT 70
10.3 HOSPITALS & MEDICAL PRACTICES 72
10.3.1 IMPROVED PATIENT CARE MANAGEMENT OFFERED BY CANCER PATIENT REGISTRY SOFTWARE TO DRIVE ITS DEMAND IN HOSPITALS AND MEDICAL PRACTICES 72
10.4 PRIVATE PAYERS 74
10.4.1 ROLE OF CANCER PATIENT REGISTRY SOFTWARE IN THE EFFECTIVE DETERMINATION OF HEALTHCARE COVERAGE POLICIES TO DRIVE ITS DEMAND AMONG PAYERS 74
10.5 PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES 76
10.5.1 INCREASED NEED FOR POST-MARKETING SURVEILLANCE DRIVING THE DEMAND FOR CANCER PATIENT REGISTRY SOFTWARE IN THIS END-USER SEGMENT 76
10.6 RESEARCH CENTERS 78
10.6.1 CANCER PATIENT REGISTRY SOFTWARE MAKES IT EASIER FOR RESEARCH CENTERS TO GATHER RELEVANT INFORMATION ON CANCER PATIENTS 78
11 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION 80
11.1 INTRODUCTION 81
11.2 NORTH AMERICA 81
11.2.1 US 85
11.2.1.1 Rising adoption of EHRs and increased government funding to build cancer registries—key drivers for market growth 85
11.2.2 CANADA 88
11.2.2.1 Government initiatives to encourage cancer research and support data collection for cancer registries to contribute to market growth 88
11.3 EUROPE 91
11.3.1 UK 95
11.3.1.1 Initiatives to promote and develop cancer registration in the UK to drive the growth of this market 95
11.3.2 GERMANY 98
11.3.2.1 Growing incidence of cancer and ongoing research activities to drive demand for registry software 98
11.3.3 FRANCE 100
11.3.3.1 Growing emphasis on healthcare interoperability to drive the market for integrated cancer patient registry software in France 100
11.3.4 REST OF EUROPE (ROE) 103
12 COMPETITIVE LANDSCAPE 106
12.1 OVERVIEW 106
12.2 MARKET PLAYER RANKING 107
12.3 COMPETITIVE SITUATION AND TRENDS 108
12.3.1 PRODUCT ENHANCEMENTS 108
12.3.2 ACQUISITIONS 108
12.3.3 COLLABORATIONS 109
13 COMPANY PROFILES 110
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 ONCO, INC. 110
13.2 C/NET SOLUTIONS 111
13.3 ELEKTA AB (PUB) 112
13.4 ROCKY MOUNTAIN CANCER DATA SYSTEMS 114
13.5 ELECTRONIC REGISTRY SYSTEMS, INC. 115
13.6 MCKESSON CORPORATION 116

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

14 APPENDIX 118
14.1 DISCUSSION GUIDE 118
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 121
14.3 RELATED REPORTS 123
14.4 AUTHOR DETAILS 124

LIST OF TABLES

TABLE 1 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE,
2017–2024 (USD MILLION) 41
TABLE 2 STANDALONE CANCER PATIENT REGISTRY SOFTWARE MARKET,
BY REGION, 2017–2024 (USD MILLION) 42
TABLE 3 NORTH AMERICA: STANDALONE CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 43
TABLE 4 EUROPE: STANDALONE CANCER PATIENT REGISTRY SOFTWARE MARKET,
BY COUNTRY, 2017–2024 (USD MILLION) 43
TABLE 5 INTEGRATED CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION,
2017–2024 (USD MILLION) 44
TABLE 6 NORTH AMERICA: INTEGRATED CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 45
TABLE 7 EUROPE: INTEGRATED CANCER PATIENT REGISTRY SOFTWARE MARKET,
BY COUNTRY, 2017–2024 (USD MILLION) 45
TABLE 8 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 47
TABLE 9 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE MODELS,
BY REGION, 2017–2024 (USD MILLION) 48
TABLE 10 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2017–2024 (USD MILLION) 49
TABLE 11 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE MODELS, BY COUNTRY/REGION, 2017–2024 (USD MILLION) 49
TABLE 12 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED MODELS,
BY REGION, 2017-2024 (USD MILLION) 50
TABLE 13 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2017-2024 (USD MILLION) 51
TABLE 14 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED MODELS, BY COUNTRY/ REGION, 2017-2024 (USD MILLION) 51
TABLE 15 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE,
2017–2024 (USD MILLION) 53
TABLE 16 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR COMMERCIAL DATABASES, BY REGION, 2017–2024 (USD MILLION) 54
TABLE 17 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR COMMERCIAL DATABASES, BY COUNTRY, 2017–2024 (USD MILLION) 55
TABLE 18 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR COMMERCIAL DATABASES, BY COUNTRY, 2017–2024 (USD MILLION) 55
TABLE 19 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC DATABASES,
BY REGION, 2017–2024 (USD MILLION) 56
TABLE 20 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC DATABASES, BY COUNTRY, 2019–2024 (USD MILLION) 57
TABLE 21 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC DATABASES, BY COUNTRY, 2019–2024 (USD MILLION) 57
TABLE 22 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY,
2017–2024 (USD MILLION) 59
TABLE 23 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REPORTING
TO MEET STATE AND FEDERAL REGULATIONS, BY REGION,
2017–2024 (USD MILLION) 60
TABLE 24 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS, BY COUNTRY,
2017–2024 (USD MILLION) 61
TABLE 25 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS, BY COUNTRY,
2017–2024 (USD MILLION) 61
TABLE 26 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY REGION, 2017–2024 (USD MILLION) 63
TABLE 27 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY COUNTRY, 2017–2024 (USD MILLION) 63
TABLE 28 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY COUNTRY, 2017–2024 (USD THOUSAND) 64
TABLE 29 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH & CLINICAL STUDIES, BY REGION, 2017–2024 (USD MILLION) 65
TABLE 30 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH & CLINICAL STUDIES, BY COUNTRY, 2017–2024 (USD MILLION) 65
TABLE 31 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH & CLINICAL STUDIES, BY COUNTRY, 2017–2024 (USD MILLION) 65
TABLE 32 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT OUTCOME EVALUATION, BY REGION, 2017–2024 (USD MILLION) 66
TABLE 33 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT OUTCOME EVALUATION, BY COUNTRY, 2017–2024 (USD MILLION) 66
TABLE 34 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT OUTCOME EVALUATION, BY COUNTRY, 2017–2024 (USD MILLION) 67
TABLE 35 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER,
2017–2024 (USD MILLION) 70
TABLE 36 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS, BY REGION,
2017–2024 (USD MILLION) 71
TABLE 37 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS,
BY COUNTRY, 2017–2024 (USD MILLION) 71
TABLE 38 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS, BY COUNTRY,
2017–2024 (USD MILLION) 72
TABLE 39 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS & MEDICAL PRACTICES, BY REGION, 2017–2024 (USD MILLION) 73
TABLE 40 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS & MEDICAL PRACTICES, BY COUNTRY, 2017–2024 (USD MILLION) 73
TABLE 41 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS & MEDICAL PRACTICES, BY COUNTRY, 2017–2024 (USD MILLION) 73
TABLE 42 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRIVATE PAYERS,
BY REGION, 2017–2024 (USD MILLION) 74
TABLE 43 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRIVATE PAYERS, BY COUNTRY, 2017–2024 (USD MILLION) 75
TABLE 44 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRIVATE PAYERS, BY COUNTRY, 2017–2024 (USD THOUSAND) 75
TABLE 45 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES, BY REGION,
2017–2024 (USD MILLION) 76
TABLE 46 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2017–2024 (USD MILLION) 77
TABLE 47 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES, BY COUNTRY,
2017–2024 (USD MILLION) 77
TABLE 48 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR RESEARCH CENTERS,
BY REGION, 2017–2024 (USD MILLION) 78
TABLE 49 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR RESEARCH CENTERS, BY COUNTRY, 2017–2024 (USD MILLION) 79
TABLE 50 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR RESEARCH CENTERS, BY COUNTRY, 2017–2024 (USD MILLION) 79
TABLE 51 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION,
2017–2024 (USD MILLION) 81
TABLE 52 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET,
BY COUNTRY, 2017–2024 (USD MILLION) 83
TABLE 53 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET,
BY TYPE, 2017–2024 (USD MILLION) 83
TABLE 54 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET,
BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 83
TABLE 55 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET,
BY DATABASE TYPE, 2017–2024 (USD MILLION) 84
TABLE 56 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET,
BY FUNCTIONALITY, 2017–2024 (USD MILLION) 84
TABLE 57 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET,
BY END USER, 2017–2024 (USD MILLION) 85
TABLE 58 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE,
2017–2024 (USD MILLION) 86
TABLE 59 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 87
TABLE 60 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE,
2017–2024 (USD MILLION) 87
TABLE 61 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY,
2017–2024 (USD MILLION) 87
TABLE 62 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER,
2017–2024 (USD MILLION) 88
TABLE 63 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE,
2017–2024 (USD MILLION) 89
TABLE 64 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 89
TABLE 65 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION) 90
TABLE 66 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION) 90
TABLE 67 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER,
2017–2024 (USD MILLION) 91
TABLE 68 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 93
TABLE 69 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE,
2017–2024 (USD MILLION) 93
TABLE 70 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 93
TABLE 71 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION) 94
TABLE 72 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION) 94
TABLE 73 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER,
2017–2024 (USD MILLION) 95
TABLE 74 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE,
2017–2024 (USD MILLION) 95
TABLE 75 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 96
TABLE 76 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE,
2017–2024 (USD MILLION) 96
TABLE 77 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY,
2017–2024 (USD MILLION) 97
TABLE 78 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER,
2017–2024 (USD MILLION) 97
TABLE 79 GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY TYPE,
2017–2024 (USD MILLION) 98
TABLE 80 GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 98
TABLE 81 GERMANY: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION) 99
TABLE 82 GERMANY: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION) 99
TABLE 83 GERMANY: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION) 100
TABLE 84 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE,
2017–2024 (USD MILLION) 100
TABLE 85 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 101
TABLE 86 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION) 101
TABLE 87 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION) 102
TABLE 88 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER,
2017–2024 (USD MILLION) 102
TABLE 89 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE,
2017–2024 (USD MILLION) 103
TABLE 90 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 103
TABLE 91 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE,
2017–2024 (USD MILLION) 104
TABLE 92 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY,
2017–2024 (USD MILLION) 104
TABLE 93 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER,
2017–2024 (USD MILLION) 105
TABLE 94 PRODUCT ENHANCEMENTS, 2016–2018 108
TABLE 95 ACQUISITIONS, 2016–2018 108
TABLE 96 COLLABORATIONS, 2016–2018 109


LIST OF FIGURES

FIGURE 1 CANCER PATIENT REGISTRY SOFTWARE: MARKET SEGMENTATION 16
FIGURE 2 RESEARCH DESIGN 18
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS 22
FIGURE 4 BOTTOM-UP APPROACH 24
FIGURE 5 TOP-DOWN APPROACH 24
FIGURE 6 DATA TRIANGULATION METHODOLOGY 25
FIGURE 7 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE,
2019 VS. 2024 (USD MILLION) 27
FIGURE 8 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL,
2019 VS. 2024 (USD MILLION) 28
FIGURE 9 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE,
2019 VS. 2024 (USD MILLION) 28
FIGURE 10 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY,
2019 VS. 2024 (USD MILLION) 29
FIGURE 11 RESEARCH CENTERS SEGMENT IS EXPECTED TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD 30
FIGURE 12 RISING PRESSURE TO IMPROVE THE QUALITY OF CARE AND REDUCE HEALTHCARE COSTS TO DRIVE MARKET GROWTH 31
FIGURE 13 INTEGRATED SOFTWARE SEGMENT TO GROW AT THE FASTEST RATE DURING THE FORECAST PERIOD 32
FIGURE 14 ON-PREMISE MODELS TO HOLD THE LARGEST SHARE OF THE MARKET IN 2019 32
FIGURE 15 COMMERCIAL DATABASE SEGMENT TO DOMINATE THE MARKET IN 2019 33
FIGURE 16 CANCER REPORTING TO MEET STATE & FEDERAL REGULATIONS SEGMENT TO DOMINATE THE MARKET IN 2019 33
FIGURE 17 HOSPITALS AND MEDICAL PRACTICES SEGMENT TO DOMINATE THE MARKET
IN 2019 34
FIGURE 18 CANCER PATIENT REGISTRY SOFTWARE: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 35
FIGURE 19 INTEGRATED SOFTWARE SEGMENT IS EXPECTED TO REGISTER HIGH GROWTH DURING THE FORECAST PERIOD 41
FIGURE 20 CLOUD-BASED MODELS SEGMENT IS EXPECTED TO WITNESS THE HIGHER CAGR DURING THE FORECAST PERIOD 47
FIGURE 21 COMMERCIAL DATABASES SEGMENT TO DOMINATE THE CANCER PATIENT REGISTRY SOFTWARE MARKET DURING THE FORECAST PERIOD 53
FIGURE 22 MEDICAL RESEARCH & CLINICAL STUDIES SEGMENT IS EXPECTED TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 59
FIGURE 23 RESEARCH CENTERS - THE FASTEST-GROWING END-USER SEGMENT IN THE CANCER PATIENT REGISTRY SOFTWARE MARKET 69
FIGURE 24 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT 82
FIGURE 25 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT 92
FIGURE 26 KEY DEVELOPMENTS IN THE CANCER PATIENT REGISTRY SOFTWARE MARKET FROM 2016 TO NOVEMBER 2018 106
FIGURE 27 CANCER PATIENT REGISTRY SOFTWARE MARKET PLAYER RANKING, 2018 107
FIGURE 28 ELEKTA AB (PUB): COMPANY SNAPSHOT 112
FIGURE 29 MCKESSON CORPORATION: COMPANY SNAPSHOT 116


★調査レポート[がん患者登録ソフトウェアの世界市場予測(~2024年)] ( Cancer Registry Software Market by Type (Standalone, Integration), Delivery (On-premise, Cloud), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care, Medical Research), End User, Region - Global Forecast to 2024 / HIT-6993) 販売に関する免責事項
[がん患者登録ソフトウェアの世界市場予測(~2024年)] ( Cancer Registry Software Market by Type (Standalone, Integration), Delivery (On-premise, Cloud), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care, Medical Research), End User, Region - Global Forecast to 2024 / HIT-6993) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆